AKB-9778 ophthalmic solution

AKB-9778 · EyePoint Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AKB-9778 ophthalmic solution, covering 2023-05-25 to 2023-05-25. Get the full timeline:

Most recent: Clinical Trial Update: Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma [Phase 2]

See pricing